Literature DB >> 17327945

Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.

Graham R Foster1, Michael W Fried, Stephanos J Hadziyannis, Diethelm Messinger, Klaus Freivogel, Ola Weiland.   

Abstract

OBJECTIVE: Patient- and virus-related factors influence the response of patients with chronic hepatitis C to interferon-based therapy. The purpose of this study was to model the probability of achieving a sustained virological response in individual patients, taking into consideration various predictive factors.
MATERIAL AND METHODS: We combined data from two randomized, multinational trials in which patients received peginterferon alfa-2a (40KD) plus ribavirin. The logistic regression model for patients infected with hepatitis C virus genotype 1 included age, viral load, histology, alanine aminotransferase quotient, body mass index, treatment duration, ribavirin dose and adherence.
RESULTS: In the genotype 1 model, varying baseline factors had a striking effect on the probability of sustained virological response. A dramatic difference in the probability of sustained virological response was seen in a series of hypothetical patients in whom five factors were varied to represent best and worst case scenarios. The best case scenario (age 20 years; no cirrhosis/bridging fibrosis; alanine aminotransferase quotient=7; body mass index 20 kg/m2; viral load 40,000 IU/mL) was associated with a 97% probability of sustained virological response, compared with 7% in the worst case scenario (age 60 years; cirrhosis/bridging fibrosis; alanine aminotransferase quotient=1; body mass index 30 kg/m2; viral load 9,000,000 IU/mL). Both adherence to treatment and achieving an early virological response increased the probability of sustained virological response.
CONCLUSIONS: In treatment-naïve patients with chronic hepatitis C, host factors play a major role in determining treatment outcome and the logistic regression model is useful for predicting the probability of sustained virological response in individual patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17327945     DOI: 10.1080/00365520600955526

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  10 in total

1.  FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.

Authors:  Keyur Patel; Mireen Friedrich-Rust; Yoav Lurie; Mircea Grigorescu; Carol Stanciu; Chuan-Mo Lee; Eugene R Schiff; Dieter Häussinger; Michael P Manns; Guido Gerken; Isabelle Colle; Michael Torbenson; Erik Pulkstenis; G Mani Subramanian; John G McHutchison; Stefan Zeuzem
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

2.  Antiviral treatment of chronic hepatitis C in clinical routine.

Authors:  Andreas Maieron; Sigrid Metz-Gercek; Franz Hackl; Alexander Ziachehabi; Harri Fuchsteiner; Christoph Luger; Helmut Mittermayer; Rainer Schöfl
Journal:  Wien Klin Wochenschr       Date:  2010-04       Impact factor: 1.704

3.  Sustained virological response based on rapid virological response in genotype-3 chronic hepatitis C treated with standard interferon in the Pakistani population.

Authors:  Bader-Faiyaz Zuberi; Faisal-Faiyaz Zuberi; Sajjad-Ali Memon; Muhammad-Hafeez Qureshi; Sheikh-Zafar Ali; Salahuddin Afsar
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

4.  The spatial distribution of BUN reference values of Chinese healthy adults: a cross-section study.

Authors:  Dezhi Wei; Miao Ge
Journal:  Int J Biometeorol       Date:  2018-10-27       Impact factor: 3.787

5.  Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.

Authors:  S K Tohra; S Taneja; S Ghosh; B K Sharma; A Duseja; R K Dhiman; A Das; Y K Chawla
Journal:  Dig Dis Sci       Date:  2011-06-25       Impact factor: 3.199

6.  The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection.

Authors:  Viola Weich; Eva Herrmann; Tje Lin Chung; Christoph Sarrazin; Holger Hinrichsen; Peter Buggisch; Tilman Gerlach; Hartwig Klinker; Ulrich Spengler; Alexandra Bergk; Stefan Zeuzem; Thomas Berg
Journal:  J Gastroenterol       Date:  2011-09-13       Impact factor: 7.527

Review 7.  Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection.

Authors:  Susan J Keam; Risto S Cvetković
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research.

Authors:  J J Weiss; N Bräu; A Stivala; T Swan; D Fishbein
Journal:  Aliment Pharmacol Ther       Date:  2009-03-26       Impact factor: 8.171

9.  Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study.

Authors:  Nanna Hansen; Niels Obel; Peer B Christensen; Mette Kjær; Alex L Laursen; Henrik B Krarup; Axel Møller; Poul Schlichting; Jens Bukh; Nina Weis
Journal:  BMC Infect Dis       Date:  2011-06-21       Impact factor: 3.090

10.  HCV infection treatment: a future full of hope.

Authors:  Majid Amiri; Katayoun Kiahashemi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2013
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.